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Abstract
Microarray data has a high dimension of variables but available datasets usually have only a small number of samples,
thereby making the study of such datasets interesting and challenging. In the task of analyzing microarray data for the
purpose of, e.g., predicting gene-disease association, feature selection is very important because it provides a way to handle
the high dimensionality by exploiting information redundancy induced by associations among genetic markers. Judicious
feature selection in microarray data analysis can result in significant reduction of cost while maintaining or improving the
classification or prediction accuracy of learning machines that are employed to sort out the datasets. In this paper, we
propose a gene selection method called Recursive Feature Addition (RFA), which combines supervised learning and
statistical similarity measures. We compare our method with the following gene selection methods:
N Support Vector Machine Recursive Feature Elimination (SVMRFE)
N Leave-One-Out Calculation Sequential Forward Selection (LOOCSFS)
N Gradient based Leave-one-out Gene Selection (GLGS) To evaluate the performance of these gene selection methods,
we employ several popular learning classifiers on the MicroArray Quality Control phase II on predictive modeling
(MAQC-II) breast cancer dataset and the MAQC-II multiple myeloma dataset. Experimental results show that gene
selection is strictly paired with learning classifier. Overall, our approach outperforms other compared methods. The
biological functional analysis based on the MAQC-II breast cancer dataset convinced us to apply our method for
phenotype prediction. Additionally, learning classifiers also play important roles in the classification of microarray data
and our experimental results indicate that the Nearest Mean Scale Classifier (NMSC) is a good choice due to its
prediction reliability and its stability across the three performance measurements: Testing accuracy, MCC values, and
AUC errors.
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Introduction
Using microarray techniques, researchers can measure the
expression levels for tens of thousands of genes in a single
experiment. This ability allows scientists to investigate the
functional relationship between the cellular and physiological
processes of biological organisms and genes at a genome-wide
level. The preprocessing procedure for the raw microarray data
consists of background correction, normalization, and summa-
rization. After preprocessing, a high level analysis, such as gene
selection, classification, or clustering, is applied to profile the
gene expression patterns [1]. In the high-level analysis,
partitioning genes into closely related groups across time and
classifying patients into different health statuses based on
selected gene signatures have become two main tracks of
microarray data analysis in the past decade [2–6]. Various
standards related to systems biology are discussed by Brazma
et al. [7]. When sample sizes are substantially smaller than the
number of features or genes, statistical modeling and inference
issues become challenging as the familiar ‘‘large p small n
problem’’ arises. Designing feature selection methods that lead
to reliable and accurate predictions by learning classifiers,
therefore, is an issue of great theoretical as well as practical
importance in high dimensional data analysis.
To address the ‘‘curse of dimensionality’’ problem, three basic
strategies have been proposed for feature selection: filtering,
PLoS ONE | www.plosone.org 1 December 2009 | Volume 4 | Issue 12 | e8250Table 1. The 34 cancer related genes of the 100 features selected by NBC-MSC on original training group of MAQC-II breast cancer
data for pCR prediction.
Symbol Synonym(s) Entrez Gene Name Affymetrix
ALB ALB1, ALBUMIN, Albumin 1, Albza, DKFZp779N1935, PRO0883, PRO0903, PRO1341,
SA, SERUM ALBUMIN, SERUM ALBUMIN CHAIN A, Serum albumin precursor
albumin 214837_at
C10ORF81 9930023K05RIK, bA211N11.2, FLJ23537, HEL185, MGC99964, RGD1559884,
RP11-211N11.2
chromosome 10 open reading frame 81 219857_at
CDK10 BC017131, MGC112847, PISSLRE cyclin-dependent kinase 10 210622_x_at
CEACAM1 bb-1, BGP, BGP1, BGPA, Bgpd, BGPI, BGPR, C-CAM, C-CAM1, CCAM105, CD66,
CD66A, Cea-1, Cea-7, CEACAM1-4L, ECTO ATPASE, HV2, mCEA1, Mhv-1, MHVR,
MHVR1, mmCGM1, mmCGM1a, mmCGM2, Pp120
carcinoembryonic antigen-related cell adhesion
molecule 1 (biliary glycoprotein)
211889_x_at
CHRNB4 Acrb-4, NACHR BETA4 cholinergic receptor, nicotinic, beta 4 207516_at
CR1 C3b/C4b receptor, C3BR, CD35, CD46, Cr1l, Crry, KN, Mcp, mCRY,
MGC102484, SCR1
complement component (3b/4b) receptor 1 (Knops
blood group)
217552_x_at
CXCL3 Cinc-2, CINC-2a, CINC-2b, Cinc3, Cxcl2, Dcip1, Gm1960, GRO ALPHA, GRO BETA,
GRO GAMMA, GRO1, Gro2, GRO3, GROA, GROb, GROg, KC, MGSA, Mgsa-b, MIP-2,
MIP-2a, MIP-2b, Mip2 alpha, N51, Scyb, Scyb2, SCYB3
chemokine (C-X-C motif) ligand 3 207850_at
CXCL13 ANGIE, ANGIE2, BCA-1, BLC, BLC1, BLR1L, CXC CHEMOKINE, Loc498335, SCYB13 chemokine (C-X-C motif) ligand 13 205242_at
DKK1 Dkk1 predicted, mdkk-1, SK dickkopf homolog 1 (Xenopus laevis) 204602_at
DRD2 D2, D2 DOPAMINE RECEPTOR, D2a dopamine receptor, D2DR, D2R, D2S,
DOPAMINE D2 RECEPTOR, Dr2
dopamine receptor D2 216924_s_at
EED HEED, l(7)5Rn, l7Rn5, lusk, WAIT-1 embryonic ectoderm development 209572_s_at
GINS3 2700085M18Rik, AI616142, FLJ13912, PSF3, RGD1308153 GINS complex subunit 3 (Psf3 homolog) 218719_s_at
GPS2 AI505953, AMF-1, MGC104294, MGC119287, MGC119288, MGC119289 G protein pathway suppressor 2 209350_s_at
GRIA2 GLUR-B, GluR-K2, GLUR2, GLUR2 IONOTROPIC, HBGR2 glutamate receptor, ionotropic, AMPA 2 205358_at
GSN DKFZp313L0718, GELSOLIN, MGC28083, MGC95032 gelsolin (amyloidosis, Finnish type) 214040_s_at
IFNAR1 ALPHA CHAIN OF TYPE I IFNR, AVP, BETA R1, CD118, Ifar, IFN RECEPTOR TYPE 1,
IFN TYPE 1 RECEPTOR, IFN-alpha-beta-R, IFN-ALPHA-REC, IFNalpha/betaR, IFNAR,
IFNBR, IFRC, Infar, INFAR1, Interferon Receptor, LOC284829, Type I infr
interferon (alpha, beta and omega) receptor 1 204191_at
ITGB4 AA407042, C230078O20, CD104, INTEGRIN-BETA 4 integrin, beta 4 204989_s_at
IVD 1300016K07Rik, 6720455E18Rik, ACAD2, AI463340, Isovaleryl-Coa Dehydrogenase isovaleryl Coenzyme A dehydrogenase 216958_s_at
KL ALPHA KLOTHO, alpha-kl, KLOTHO klotho 205978_at
N4BP1 AI481586, C81621, FLJ31821, KIAA0615, MGC176730, MGC7607, RGD1305179 NEDD4 binding protein 1 32069_at
NAIP AV364616, BIRC1, BIRC1A, Birc1b, Birc1e, BIRC1F, D13Lsd1, FLJ18088, FLJ42520,
FLJ58811, LGN1, LOC652755, Naip-rs1, Naip-rs3, Naip-rs4, Naip-rs4A, Naip1,
Naip2, Naip5, Naip6, NLRB1, psiNAIP, RGD1559914
NLR family, apoptosis inhibitory protein 204861_s_at
NDST1 1200015G06RIK, HSNST, HSST, HSST1, NST1 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 202608_s_at






PAWR PAR-4 PRKC, apoptosis, WT1, regulator 204005_s_at
PDPK1 MGC20087, MGC35290, PDK1, PRO0461 3-phosphoinositide dependent protein kinase-1 204524_at




9630030H21, GADD34, MYD116, Myeloid Differentiation, Peg-3, PP1
REGULATORY SUBUNIT, Ppp1r15a
protein phosphatase 1, regulatory (inhibitor)
subunit 15A
202014_at
RASSF1 123F2, AA536941, AU044980, D4Mgi37, MGC94319, NORE2A, PTS,
Rassf1A, Rassf1B, Rassf1C, RDA32, REH3P21
Ras association (RalGDS/AF-6) domain family member 1 204346_s_at
SYT1 AW124717, DKFZp781D2042, G630098F17Rik, P65, SVP65, SYNAPTOTAGMIN 1, SYT synaptotagmin I 203999_at
TACSTD2 C80403, EGP-1, GA733, GA733-1, Ly97, M1S1, MGC141612, MGC141613,
MGC72570, Prp1, TROP2
tumor-associated calcium signal transducer 2 202286_s_at
TEK AA517024, CD202B, Hyk, MGC139569, TIE-2, VMCM, VMCM1 TEK tyrosine kinase, endothelial 206702_at
TTF1 AV245725, RGD1565673, Ttf-I transcription termination factor, RNA polymerase I 204772_s_at
ZEB1 3110032K11Rik, AREB6, BZP, DELTA-EF1, MEB1, MGC133261, NIL-2-A,
Nil2, Tcf18, TCF8, TCP8, TF8, TRANSCRIPTION FACTOR 8, ZEB, ZFHEP, Zfhep2,
ZFHX1A, Zfx1a, Zfx1ha, [delta]EF1
zinc finger E-box binding homeobox 1 212758_s_at
ZNF10 KOX1 zinc finger protein 10 216350_s_at
doi:10.1371/journal.pone.0008250.t001
MAQC-II Gene Expression
PLoS ONE | www.plosone.org 2 December 2009 | Volume 4 | Issue 12 | e8250Table 2. The 34 cancer related genes of the 100 features selected by NMSC-MSC on original training group of MAQC-II breast
cancer data for pCR prediction.
Symbol Synonym(s) Entrez Gene Name Affymetrix
ALB ALB1, ALBUMIN, Albumin 1, Albza, DKFZp779N1935, PRO0883, PRO0903,
PRO1341, SA, SERUM ALBUMIN, SERUM ALBUMIN CHAIN A, Serum albumin
precursor
albumin 214837_at
ARAF 1200013E08Rik, ARAF1, AW495444, PKS, PKS2, RAFA1 v-raf murine sarcoma 3611 viral oncogene
homolog
201895_at
C10ORF81 9930023K05RIK, bA211N11.2, FLJ23537, HEL185, MGC99964, RGD1559884,
RP11-211N11.2
chromosome 10 open reading frame 81 219857_at
CDH1 AA960649, Arc-1, Cadherin 1, CD324, CDHE, CSEIL, E-CADHERIN, E-CADHERIN
120 KDA, ECAD, L-CAM, MGC107495, Um, UVO, uvomorulin
cadherin 1, type 1, E-cadherin (epithelial) 201131_s_at
CDK10 BC017131, MGC112847, PISSLRE cyclin-dependent kinase 10 210622_x_at
CEACAM1 bb-1, BGP, BGP1, BGPA, Bgpd, BGPI, BGPR, C-CAM, C-CAM1, CCAM105, CD66,
CD66A, Cea-1, Cea-7, CEACAM1-4L, ECTO ATPASE, HV2, mCEA1, Mhv-1, MHVR,
MHVR1, mmCGM1, mmCGM1a, mmCGM2, Pp120
carcinoembryonic antigen-related cell adhesion
molecule 1 (biliary glycoprotein)
211889_x_at
CEBPE C/EBP EPSILON, C/EBPe, C/EPBe, CRP1, Gm294, MGC124002, MGC124003 CCAAT/enhancer binding protein (C/EBP), epsilon 214523_at
CHRNB4 Acrb-4, NACHR BETA4 cholinergic receptor, nicotinic, beta 4 207516_at
CR1 C3b/C4b receptor, C3BR, CD35, CD46, Cr1l, Crry, KN, Mcp, mCRY,
MGC102484, SCR1
complement component (3b/4b) receptor 1
(Knops blood group)
217552_x_at
CXCL3 Cinc-2, CINC-2a, CINC-2b, Cinc3, Cxcl2, Dcip1, Gm1960, GRO ALPHA, GRO
BETA, GRO GAMMA, GRO1, Gro2, GRO3, GROA, GROb, GROg, KC, MGSA,
Mgsa-b, MIP-2, MIP-2a, MIP-2b, Mip2 alpha, N51, Scyb, Scyb2, SCYB3
chemokine (C-X-C motif) ligand 3 207850_at
CXCL13 ANGIE, ANGIE2, BCA-1, BLC, BLC1, BLR1L, CXC CHEMOKINE, Loc498335, SCYB13 chemokine (C-X-C motif) ligand 13 205242_at
DRD2 D2, D2 DOPAMINE RECEPTOR, D2a dopamine receptor, D2DR, D2R, D2S,
DOPAMINE D2 RECEPTOR, Dr2
dopamine receptor D2 216924_s_at
DYRK1A 2310043O08Rik, D16Ertd272e, D16Ertd493e, DUAL-SPECIFICITY TYROSINE-(Y)-
PHOSPHORYLATION REGULATED KINASE 1A, DYRK, DYRK1, HP86, MGC150253,




EPOR EP-R, ERYTHROPOIETIN RECEPTOR, MGC108723, MGC138358 erythropoietin receptor 215054_at
FAM153A KIAA0752, NY-REN-7 family with sequence similarity 153, member A 211166_at
GINS3 2700085M18Rik, AI616142, FLJ13912, PSF3, RGD1308153 GINS complex subunit 3 (Psf3 homolog) 218719_s_at
GRIA2 GLUR-B, GluR-K2, GLUR2, GLUR2 IONOTROPIC, HBGR2 glutamate receptor, ionotropic, AMPA 2 205358_at
GSN DKFZp313L0718, GELSOLIN, MGC28083, MGC95032 gelsolin (amyloidosis, Finnish type) 214040_s_at
IFNAR1 ALPHA CHAIN OF TYPE I IFNR, AVP, BETA R1, CD118, Ifar, IFN RECEPTOR TYPE 1,
IFN TYPE 1 RECEPTOR, IFN-alpha-beta-R, IFN-ALPHA-REC, IFNalpha/betaR, IFNAR,
IFNBR, IFRC, Infar, INFAR1, Interferon Receptor, LOC284829, Type I infr
interferon (alpha, beta and omega) receptor 1 204191_at
ITGB4 AA407042, C230078O20, CD104, INTEGRIN-BETA 4 integrin, beta 4 204989_s_at
KL ALPHA KLOTHO, alpha-kl, KLOTHO klotho 205978_at
LPAR1 5031439C20, AI326300, clone 4.9, EDG2, ENDOTHELIAL DIFFERENTIATION
LYSOPHOSPHATIDIC ACID G-PROTEIN-COUPLED RECEPTOR 2, Gpcr26, GPR26,
Kdt2, LPA receptor 1, LPA1, LPA1 RECEPTOR, LPA2, LYSOPHOSPHATIDIC ACID
G-PROTEIN-COUPLED RECEPTOR, MGC105279, MGC29102, Mrec1.3, rec.1.3, vzg-1
lysophosphatidic acid receptor 1 204037_at
MCF2 B230117G22Rik, DBL, MGC159138, RGD1566098 MCF.2 cell line derived transforming sequence 208017_s_at
MYO10 AW048724, D15Ertd600e, FLJ10639, FLJ21066, FLJ22268, FLJ43256, KIAA0799,
MGC131988, mKIAA0799, Myo10 (predicted), myosin-X
myosin X 201976_s_at
NAIP AV364616, BIRC1, BIRC1A, Birc1b, Birc1e, BIRC1F, D13Lsd1, FLJ18088, FLJ42520,
FLJ58811, LGN1, LOC652755, Naip-rs1, Naip-rs3, Naip-rs4, Naip-rs4A, Naip1,
Naip2, Naip5, Naip6, NLRB1, psiNAIP, RGD1559914
NLR family, apoptosis inhibitory protein 204860_s_at
NDST1 1200015G06RIK, HSNST, HSST, HSST1, NST1 N-deacetylase/N-sulfotransferase (heparan
glucosaminyl) 1
202608_s_at
PHLDA1 DT1P1B11, MGC131738, PHRIP, PQ-RICH, Proline- and glutamine-rich, TDAG,
TDAG51






9630030H21, GADD34, MYD116, Myeloid Differentiation, Peg-3, PP1
REGULATORY SUBUNIT, Ppp1r15a
protein phosphatase 1, regulatory (inhibitor)
subunit 15A
202014_at
RASSF1 123F2, AA536941, AU044980, D4Mgi37, MGC94319, NORE2A, PTS, Rassf1A,
Rassf1B, Rassf1C, RDA32, REH3P21
Ras association (RalGDS/AF-6) domain family
member 1
204346_s_at
SIAH1 AA982064, AI853500, D9MGI7, FLJ08065, hSIAH1, HUMSIAH, SIAH, Siah1a, Sinh1a seven in absentia homolog 1 (Drosophila) 202981_x_at
TTF1 AV245725, RGD1565673, Ttf-I transcription termination factor, RNA polymerase I 204772_s_at
MAQC-II Gene Expression
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8250Symbol Synonym(s) Entrez Gene Name Affymetrix
VAMP2 FLJ11460, mVam2, RATVAMPB, RATVAMPIR, SYB, SYB2, SYNAPTOBREVIN 2,
Vamp ii
vesicle-associated membrane protein 2
(synaptobrevin 2)
201557_at
ZNF10 KOX1 zinc finger protein 10 216350_s_at
ZNF205 4933429B21, AI835008, Krox-8, Zfp13, ZINC FINGER PROTEIN 205, ZNF210 zinc finger protein 205 206416_at
doi:10.1371/journal.pone.0008250.t002
Table 2. Cont.
Table 3. The 26 cancer related genes of the 100 features selected by GLGS on original training group of MAQC-II breast cancer
data for pCR prediction.
Symbol Synonym(s) Entrez Gene Name Affymetrix
ADAM15 MDC15, METARGIDIN, tMDCVI ADAM metallopeptidase domain 15 217007_s_at
ARAF 1200013E08Rik, ARAF1, AW495444, PKS, PKS2, RAFA1 v-raf murine sarcoma 3611 viral oncogene homolog 201895_at
ASNS AS, ASPARAGINE SYNTHETASE, MGC93148, TS11 asparagine synthetase 205047_s_at
B4GALT5 9430078I07Rik, AW049941, AW539721, BETA4-GALT-IV, beta4Gal-T5,
beta4GalT-V, gt-V, MGC138470
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase,
polypeptide 5
221485_at
CEACAM1 bb-1, BGP, BGP1, BGPA, Bgpd, BGPI, BGPR, C-CAM, C-CAM1, CCAM105,
CD66, CD66A, Cea-1, Cea-7, CEACAM1-4L, ECTO ATPASE, HV2, mCEA1,
Mhv-1, MHVR, MHVR1, mmCGM1, mmCGM1a, mmCGM2, Pp120
carcinoembryonic antigen-related cell adhesion
molecule 1 (biliary glycoprotein)
211889_x_at
CXCL3 Cinc-2, CINC-2a, CINC-2b, Cinc3, Cxcl2, Dcip1, Gm1960, GRO ALPHA, GRO
BETA, GRO GAMMA, GRO1, Gro2, GRO3, GROA, GROb, GROg, KC, MGSA,
Mgsa-b, MIP-2, MIP-2a, MIP-2b, Mip2 alpha, N51, Scyb, Scyb2, SCYB3
chemokine (C-X-C motif) ligand 3 207850_at
CYCS (includes
EG:54205)
CYC, CYCS, CYCSA, CYCT, CYCTA, CYTC, CYTOCHROME C, HCS,
MGC93634, T-Cc
cytochrome c, somatic 208905_at
DRD2 D2, D2 DOPAMINE RECEPTOR, D2a dopamine receptor, D2DR, D2R,
D2S, DOPAMINE D2 RECEPTOR, Dr2
dopamine receptor D2 216924_s_at
EGFR 9030024J15RIK, AI552599, EGF RECEPTOR, EGF-TK, EGFR1, EGFRec, ER2,
ERBB, ERBB1, Errp, HER1, MENA, PIG61, wa-2, Wa5
epidermal growth factor receptor (erythroblastic
leukemia viral (v-erb-b) oncogene homolog, avian)
201983_s_at
FBLN1 FBLN, FIBULIN 1 fibulin 1 207834_at
FIS1 2010003O14Rik, CGI-135, Riken cDNA 2010003o14, TTC11 fission 1 (mitochondrial outer membrane) homolog
(S. cerevisiae)
218034_at
FOXC1 ARA, ch, fkh-1, FKHL7, FLJ11796, FLJ11796 FIS, FREAC-3, frkhda,
IGDA, IHG1, IRID1, Mf1, Mf4, rCG 44068, rCG_44068
forkhead box C1 213260_at
FTL FERRITIN LIGHT CHAIN, FTL1, Ftl2, L-FERRITIN, MGC102130, MGC102131,
MGC118079, MGC118080, MGC71996, RGD1560687, RGD1561055,
RGD1566189, YB24D08
ferritin, light polypeptide 201265_at
GFRA1 AU042498, GDNFR, Gdnfr alpha, GDNFRA, GFR-ALPHA-1, GRFA1,
MGC23045, Ret, RET1L, RETL1, TRNR1
GDNF family receptor alpha 1 205696_s_at
ITGB4 AA407042, C230078O20, CD104, INTEGRIN-BETA 4 integrin, beta 4 204989_s_at
KL ALPHA KLOTHO, alpha-kl, KLOTHO klotho 205978_at
LEF1 3000002B05, AI451430, DKFZp586H0919, LEF, TCF/LEF, TCF1ALPHA lymphoid enhancer-binding factor 1 221557_s_at
LMO4 A730077C12Rik, Crp3, Etohi4, MGC105593 LIM domain only 4 209205_s_at
LPAR2 EDG-4, FLJ93869, IPA2, LPA receptor 2, LPA2, LPA2 RECEPTOR, Pbx4,
RGD1561336
lysophosphatidic acid receptor 2 206723_s_at
MKI67 D630048A14Rik, KI-67, KIA, MIB1, MIKI67A, MKI67A antigen identified by monoclonal antibody Ki-67 212022_s_at
NAIP AV364616, BIRC1, BIRC1A, Birc1b, Birc1e, BIRC1F, D13Lsd1, FLJ18088,
FLJ42520, FLJ58811, LGN1, LOC652755, Naip-rs1, Naip-rs3, Naip-rs4,
Naip-rs4A, Naip1, Naip2, Naip5, Naip6, NLRB1, psiNAIP, RGD1559914
NLR family, apoptosis inhibitory protein 204861_s_at
PPP1R15A (includes
EG:23645)
9630030H21, GADD34, MYD116, Myeloid Differentiation, Peg-3, PP1
REGULATORY SUBUNIT, Ppp1r15a
protein phosphatase 1, regulatory (inhibitor)
subunit 15A
202014_at
RARB A830025K23, BETA RAR, HAP, LOC51036, NR1B2, RAR BETA,
RAR-EPSILON, RRB2
retinoic acid receptor, beta 208530_s_at
TEK AA517024, CD202B, Hyk, MGC139569, TIE-2, VMCM, VMCM1 TEK tyrosine kinase, endothelial 206702_at
TTF1 AV245725, RGD1565673, Ttf-I transcription termination factor, RNA polymerase I 204772_s_at
USF2 bHLHb12, FIP, MGC91056 upstream transcription factor 2, c-fos interacting 202152_x_at
doi:10.1371/journal.pone.0008250.t003
MAQC-II Gene Expression



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8250wrapper, and embedded methods. Filtering methods select
subset features independently from the learning classifiers and
do not incorporate learning [8–11]. One of the weaknesses of
filtering methods is that they only consider the individual feature
in isolation and ignore the possible interaction among features.
Yet the combination of certain features may have a net effect
that does not necessarily follow from the individual performance
of features in that group [12]. A consequence of the filtering
m e t h o d si st h a tw em a ye n du pw i t hs e l e c t i n gg r o u p so f
highly correlated features/genes, which present redundant
information to the learning classifier to ultimately worsen its
performance. Also, if there is a practical limit on the number of
features to be chosen, one may not be able to include all
informative features.
To avoid the weakness of filtering methods, wrapper methods
wrap around a particular learning algorithm that can assess the
selected feature subsets in terms of the estimated classification
errors and then build the final classifier [13]. Wrapper methods
use a learning machine to measure the quality of subsets of
features. One recent well-known wrapper method for feature/gene
selection is Support Vector Machine Recursive Feature Elimina-
tion (SVMRFE) [14], which refines the optimum feature set by
using Support Vector Machines (SVM). The idea of SVMRFE is
that the orientation of the separating hyper-plane found by the
SVM can be used to select informative features; if the plane is
orthogonal to a particular feature dimension, then that feature is
informative, and vice versa. In addition to microarray data
analysis, SVMRFE has been widely used in high-throughput
biological data analyses and other areas involving feature selection
and pattern classification [15].
Wrapper methods can noticeably reduce the number of features
and significantly improve the classification accuracy [16,17].
However, wrapper methods have the drawback of high compu-
tational load, making them less desirable as the dimensionality
increases. The embedded methods perform feature selection
simultaneously with learning classifiers to achieve better compu-
tational efficiency than wrapper methods while maintaining
similar performance. LASSO [18,19], logic regression with the
regularized Laplacian prior [20], and Bayesian regularized neural
network with automatic relevance determination [21] are
examples of embedded methods.
To improve classification of microarray data, Zhou and Mao
proposed SFS-LS bound and SFFS-LS bound algorithms for
optimal gene selection by combining the sequential forward
selection (SFS) and sequential floating forward selection (SFFS)
with LS (Least Squares) bound measure [22]. Tang et al. designed
two methods of gene selection, leave-one-out calculation sequen-
tial forward selection (LOOCSFS) and the gradient based leave-
one-out gene selection (GLGS) [23]. Diaz-Uriarte and De Andres
[24] presented a method for gene selection by calculating the out
of bag errors with random forest [25].
In human genetic research, exploiting information redundancy
from highly correlated genes can potentially reduce the cost and
simultaneously improve the reliability and accuracy of learning
classifiers that are employed in data analysis. To exploit the
information redundancy that exists among the huge number of
variables and improve classification accuracy of microarray data,
we propose a gene selection method, Recursive Feature Addition
(RFA), which is based on supervised learning and similarity
measures. We compare RFA with SVMRFE, LOOCSFS, and
GLGS by using the MAQC-II breast cancer dataset to predict pre-
operative treatment response (pCR) and estrogen receptor status
(erpos) and compare RFA with SVMRFE and LOOCSFS on the



































































































































































































































































































































































































































































































































































































































































































































































































































































































PLoS ONE | www.plosone.org 8 December 2009 | Volume 4 | Issue 12 | e8250Table 7. The 33 cancer related genes of the 100 features selected by NMSC-MSC on original training group of MAQC-II breast
cancer data for erpos prediction.
Symbol Synonym(s) Entrez Gene Name Affymetrix
BAG1 BAG1L, Bag1s, RAP46 BCL2-associated athanogene 202387_at
CCDC28A 1700009P13Rik, AI480677, C6ORF80, CCRL1AP, DKFZP586D0623,
MGC116395, MGC131913, MGC19351, RGD1310326
coiled-coil domain containing 28A 209479_at
CEACAM1 bb-1, BGP, BGP1, BGPA, Bgpd, BGPI, BGPR, C-CAM, C-CAM1, CCAM105,
CD66, CD66A, Cea-1, Cea-7, CEACAM1-4L, ECTO ATPASE, HV2, mCEA1,





CHRNB4 Acrb-4, NACHR BETA4 cholinergic receptor, nicotinic, beta 4 207516_at
EIF1 A121, EIF1A, ISO1, MGC101938, MGC6503, SUI1, SUI1-RS1 eukaryotic translation initiation factor 1 212130_x_at
EPOR EP-R, ERYTHROPOIETIN RECEPTOR, MGC108723, MGC138358 erythropoietin receptor 215054_at
FBLN1 FBLN, FIBULIN 1 fibulin 1 207834_at
GBP1 (includes EG:2633) 5830475C06, GBP1, GBPI, IFI67-K, MAG-1, MGC124334, Mpa-1 guanylate binding protein 1, interferon-
inducible, 67kDa
202270_at
GHR AA986417, GHBP, GHR/BP, GROWTH HORMONE RECEPTOR, MGC124963,
MGC156665
growth hormone receptor 205498_at
GPC3 DGSX, Glypican 3, GTR2-2, MGC93606, OCI-5, SDYS, SGB, SGBS, SGBS1 glypican 3 209220_at
GPS2 AI505953, AMF-1, MGC104294, MGC119287, MGC119288, MGC119289 G protein pathway suppressor 2 209350_s_at
IMPDH2 ENSMUSG00000071041, Imp dehydrogenase 2, IMPD, IMPD2, Impdh, IMPDH-II,




ING4 D6Wsu147e, D6Xrf92, MGC12557, MGC156688, my036, p29ING4, p33ING1
ISOLOG
inhibitor of growth family, member 4 218234_at
ITGB4 AA407042, C230078O20, CD104, INTEGRIN-BETA 4 integrin, beta 4 204990_s_at
KLF5 4930520J07Rik, BTEB2, CKLF, IKLF, Kruppel-like factor 5, mBTEB2 Kruppel-like factor 5 (intestinal) 209211_at
MAP3K12 DLK, MUK, PK, ZPK, ZPKP1 mitogen-activated protein kinase kinase
kinase 12
205447_s_at
MFAP3L 4933428A15RIK, 5430405D20Rik, AI461995, AW125052, KIAA0626, mKIAA0626,
NYD-sp9
microfibrillar-associated protein 3-like 210493_s_at
NCOR1 5730405M06RIK, A230020K14RIK, hCIT529I10, hN-CoR, KIAA1047,
MGC104216, MGC116328, mKIAA1047, N-COR, RIP13, Rxrip13, TRAC1
nuclear receptor co-repressor 1 200854_at
PA2G4 38kDa, AA672939, EBP1, HG4-1, Itaf45, MGC94070, p38-2G4, Plfap,
PROLIFERATION ASSOCIATED 2G4, Proliveration-associated protein 1
proliferation-associated 2G4, 38kDa 214794_at
PCNA MGC8367, Pcna/cyclin, PCNAR proliferating cell nuclear antigen 217400_at
PLA2G16 ADPLA, C78643, H-REV107-1, HRASLS3, HREV107, HREV107-3, MGC118754 phospholipase A2, group XVI 209581_at
PLD1 AA536939, C85393, Pc-Plc, Phospholipase D1, PLD1A, PLD1B, Plda, Pldb phospholipase D1, phosphatidylcholine-
specific
215723_s_at
PTPN14 C130080N23RIK, MGC126803, OTTMUSG00000022087, PEZ, PTP36, PTPD2 protein tyrosine phosphatase, non-
receptor type 14
205503_at
SCGB1D2 BU101, LIPB, LIPOPHILIN B, LPHB secretoglobin, family 1D, member 2 206799_at
SEL1L AW493766, IBD2, KIAA4137, mKIAA4137, PRO1063, SEL1, SEL1-LIKE, SEL1H sel-1 suppressor of lin-12-like (C. elegans) 202063_s_at
SERPINA6 AI265318, AV104445, CBG, MGC112780 serpin peptidase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 6
206325_at
SMC4 2500002A22Rik, C79747, CAP-C, DKFZP434F205, HCAP-C, MGC125078,
SMC4L1
structural maintenance of chromosomes 4 215623_x_at
SPAM1 (includes EG:6677) 4933439A12Rik, HYA1, HYAL1, HYAL3, HYAL5, MGC108951, MGC26532,
PH-20,
S P A G 1 5 ,S P A M 1 ,T E S T I C U L A RH Y A L U R O N I D A S E
sperm adhesion molecule 1 (PH-20
hyaluronidase, zona pellucida binding)
210536_s_at
TCF3 A1, AA408400, ALF2, AW209082, bHLHb21, E12, E12/E47, E2-5, E2A,
E 4 7 ,I T F 1 ,M E 2 ,M G C 1 2 9 6 4 7 ,M G C 1 2 9 6 4 8 ,P A N 1 ,P a n 2 ,T c f e 2 a ,
TRANSCRIPTION FACTOR 3, VDIR
transcription factor 3 (E2A immunoglobulin
enhancer binding factors E12/E47)
213730_x_at
TGFA RATTGFAA, TFGA, TGF ALPHA, TGFAA, wa-1 transforming growth factor, alpha 211258_s_at
TNFRSF11A CD265, FEO, LOH18CR1, Ly109, MGC112793, mRANK, ODAR, ODFR,
OFE, OPGL receptor, OPTB7, OSTS, PDB2, RANK, RGD1563614, TRANCE-R
tumor necrosis factor receptor superfamily,
member 11a, NFKB activator
207037_at
TNFSF12 APO3L, DR3L, DR3LG, MGC129581, MGC20669, TWEAK tumor necrosis factor (ligand) superfamily,
member 12
205611_at
USP7 2210010O09Rik, AA409944, AA617399, AU019296, AW548146, C80752,
HAUSP, TEF1




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































PLoS ONE | www.plosone.org 11 December 2009 | Volume 4 | Issue 12 | e8250Table 9. The 44 cancer related genes of the 100 features selected by LOOCSFS on original training group of MAQC-II breast cancer
data for erpos prediction.
Symbol Synonym(s) Entrez Gene Name Affymetrix
ACP1 4632432E04Rik, AI427468, HAAP, LMPTP, LMW-PTP, MGC103115,
MGC111030, MGC132904, MGC3499
acid phosphatase 1, soluble 215227_x_at
BAG1 BAG1L, Bag1s, RAP46 BCL2-associated athanogene 202387_at
BCL2 AW986256, Bcl2 alpha, C430015F12Rik, CED9, D630044D05RIK,
D830018M01RIK, LOC100046608, ORF16
B-cell CLL/lymphoma 2 203685_at
BTG2 AA959598, Agl, An, an-1, APRO1, B-cell translocation gene 2,
antiproliferative, MGC126063, MGC126064, PC3, TIS21
BTG family, member 2 201236_s_at
CCDC28A 1700009P13Rik, AI480677, C6ORF80, CCRL1AP, DKFZP586D0623,
MGC116395, MGC131913, MGC19351, RGD1310326
coiled-coil domain containing 28A 209479_at
CCNA2 AA408589, CCN1, CCNA, CYCA, CYCLIN A2, CYCLIN-A, MGC156527, p60 cyclin A2 213226_at
CD47 9130415E20RIK, AA407862, AI848868, AW108519, B430305P08RIK, CD47
ANTIGEN, CDw149, IAP, Itgp, Locuslink 71587, MER6, MGC93490, OA3
CD47 molecule 211075_s_at
CFD ADIPSIN, ADN, Complement Factor D, DF, EVE, FACTOR D, PFD complement factor D (adipsin) 205382_s_at
CHRNA5 AChR alpha5, Acra-5, ALPHA5 NACHR, ALPHA5 NICOTINIC RECEPTOR,
LNCR2, MGC124059, MGC124168, nAChR alpha5, sialoprotein
cholinergic receptor, nicotinic, alpha 5 206533_at
CTSL2 1190035F06Rik, Cathepsin l, CATHEPSIN V, CATHL, CATL2, Ctsl, Ctsl1,
CTSU, CTSV, fs, MEP, MGC125957, nkt
cathepsin L2 210074_at
CXCL10 C7, CRG-2, GAMMA-IFN INDUCIBLE EARLY RESPONSE, gIP-10, IFI10, IFNG
INDUCIBLE PROTEIN-10, INP10, Interferon-inducible protein-10, IP-10, mob-1,
SCYB10, SMALL INDUCIBLE CYTOKINE SUBFAMILY B (Cys-X-Cys), MEMBER 10
chemokine (C-X-C motif) ligand 10 204533_at
CYB5A 0610009N12Rik, CB5, CYB5, Cytb5, CYTOCHROME B5, MCB5, MGC108694,
MGC128769
cytochrome b5 type A (microsomal) 209366_x_at
DDX17 2610007K22RIK, A430025E01Rik, AI047725, C80929, DEAD-box protein
p72, DEAD/H box RNA helicase p72, DKFZp761H2016, Gm926,
MGC109323, MGC79147, P72, RH70
DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 208718_at
DNMT3B DNA MTase HsaIIIB, ICF, M.HsaIIIB, MGC124407 DNA (cytosine-5-)-methyltransferase 3 beta 220668_s_at
EPHA2 AW545284, ECK, ECKR, Myk2, Sek-2 EPH receptor A2 203499_at
ERBB4 C-erb-b4, Erbb4 Cyt2, ERBB4 JM-A, HER4, MGC138404, p180erbB4 v-erb-a erythroblastic leukemia viral oncogene
homolog 4 (avian)
214053_at
ESR1 AA420328, Alpha estrogen receptor, AU041214, DKFZp686N23123,
ER, ER ALPHA, Er alpha (46 kDa isoform), ER66, ERA, ER[a], ESR, ESRA,
ESTR, ESTRA, ESTROGEN RECEPTOR ALPHA, ESTROGEN RECEPTOR1,
NR3A1, RNESTROR, TERP-1
estrogen receptor 1 205225_at
ETV5 1110005E01Rik, 8430401F14Rik, ERM ets variant 5 203349_s_at
FAM134B 1810015C04RIK, AU015349, FLJ20152, FLJ22155, FLJ22179 family with sequence similarity 134, member B 218510_x_at
FBLN1 FBLN, FIBULIN 1 fibulin 1 207834_at
GREB1 5730583K22Rik, 9130004E13, AF180470, AU023194, KIAA0575, mKIAA0575 GREB1 protein 205862_at
IL6ST 5133400A03Rik, AA389424, Ac1055, BB405851, CD130, CDw130,
D13Ertd699e, GP130, GP130-RAPS, Il6 transd, IL6R-beta
interleukin 6 signal transducer (gp130, oncostatin M
receptor)
211000_s_at
IRS1 ENSMUSG00000022591, G972R, HIRS-1, IRS1IRM insulin receptor substrate 1 204686_at
ITPR1 D6Pas2, I145TR, InsP3R, INSP3R1, IP3 RECEPTOR, Ip3 Receptor Type 1,
IP3R, IP3R1, opt, P400, Pcd6, Pcp-1, SCA15, SCA16
inositol 1,4,5-triphosphate receptor, type 1 203710_at
LRP8 4932703M08Rik, AA921429, AI848122, APOER2, HSZ75190, LR8B, MCI1 low density lipoprotein receptor-related protein 8,
apolipoprotein e receptor
208433_s_at
MAP3K12 DLK, MUK, PK, ZPK, ZPKP1 mitogen-activated protein kinase kinase kinase 12 205447_s_at
MAPT AI413597, ALZ50, AW045860, DDPAC, FLJ31424, FTDP-17, MAPTL,
MGC134287, MGC138549, MGC156663, MSTD, Mtapt, MTBT1, MTBT2, PHF
TAU, PPND, pTau, RNPTAU, TAU, Tau 3r, Tau-1, TAU-FACTOR, Tau40, TAU4R
microtubule-associated protein tau 203929_s_at
MCM7 AI747533, CDABP0042, CDC47, D16Mgi24, mCDC47, MCM2, Mcmd7,




MYO10 AW048724, D15Ertd600e, FLJ10639, FLJ21066, FLJ22268, FLJ43256,




CAP-G, CHCG, FLJ12450, HCAP-G, MGC126525, NCAPG, NY-MEL-3,
RGD1562646
non-SMC condensin I complex, subunit G 218663_at
NDRG1 CAP43, CMT4D, DRG1, GC4, HMSNL, N-myc Downstream Regulated 1,
N-myc downstream regulatory protein 1, NDR1, NDRL, NMSL, PROXY1,
RIT42, RTP, TARG1, TDD5
N-myc downstream regulated 1 200632_s_at
MAQC-II Gene Expression
PLoS ONE | www.plosone.org 12 December 2009 | Volume 4 | Issue 12 | e8250milestone outcome (OSMO, 730-day cutoff) and to predict event-
free survival milestone outcome (EFSMO, 730-day cutoff).
Results
Results on MAQC-II Breast Cancer Dataset
We compare MSC-based RFA methods with GLGS,
LOOCSFS, and SVMRFE on MAQC-II breast cancer dataset.
Tables 1 to 10 list the cancer related genes of the first 100 features
selected by these methods. In comparison to GLGS, LOOCSFS,
and SVMRFE, RFA is associated with a greater number of
currently known cancer related genes for prediction of pCR and a
smaller number of currently known cancer related genes for
prediction of erpos. Since disease status is not simply related to the
number of these cancer related genes, we obtain the prediction
performance by running multiple experiments, and compare the
average prediction performance using the following measure-
ments: testing accuracy, Matthews Correlation Coefficients (MCC)
[26,27] that has been used in MAQC-II consortium [28], and area
under the receiver operating curve (AUC) errors with classifiers
NMSC, NBC, SVM and UDC (uncorrelated normal based
quadratic Bayes classifier) [29].
Figure 1 lists the testing accuracy, MCC values, and AUC
errors on prediction of erpos by using two RFA methods: NBC-
MSC and NMSC-MSC, as well as GLGS, LOOCSFS, and
SVMRFE with the four learning classifiers. Regarding the
prediction performance evaluated using testing accuracy and
MCC values (left column and middle column, Fig. 1), on average
the two RFA methods NBC-MSC and NMSC-MSC outperform
other compared gene selection methods. The advantage of RFA
by using NMSC and UDC is especially noticeable.
We notice that the performance evaluation using testing
accuracy (left column) and MCC (middle column) is consistent,
but the performance evaluation using AUC measurement is not
always consistent with the evaluation using testing accuracy and
MCC. For instance, in applying UDC to the feature sets, RFA
methods have the best prediction performance evaluated using
testing accuracy and MCC values; however, with respect to
performance evaluated using AUC errors RFA is not the best.
Regarding the testing performance measured by using AUC
errors, the best results have been obtained by using RFA with
NMSC classifier. The AUC errors are as low as 0.08, which is
much better than the results by using other methods of gene
selection.
The prediction results on pCR endpoint, shown in Figure 2,
also demonstrate the advantage of RFA methods over other
compared methods. All the best prediction results, evaluated by
using AUC, MCC and testing accuracy, are obtained by using
RFA methods.
Tables 11 and 12 list the average testing under the best training,
MS_HR, and the best testing under the best training, HS_HR, for
the predictions on erpos and pCR, respectively. Figure 3 and
Figure 4 show box-plots of MS_HR values for the predictions on
erpos and pCR. The results indicate that the prediction
performance depends not only on gene selection but also on
learning classifier. In other words, gene selection and classifier are
coupled in determining prediction performance. On average, RFA
gene selection methods deliver the best performance, followed by
GLGS; NMSC classifier outperforms the others with respect to the
performance and the consistency across the three measurements.
The combination of RFA with NMSC has the best overall
prediction performance.
Results on MAQC-II Multiple Myeloma Dataset
Figures 5 and 6 show the box-plots of average testing values for
EFSMO and OSMO, the classification models are based on the
best training. We did not apply GLGS because it would take an
Symbol Synonym(s) Entrez Gene Name Affymetrix
NOTCH3 AW229011, CADASIL, CASIL Notch homolog 3 (Drosophila) 203238_s_at
NPY1R MGC109393, NPY receptor Y1, NPY Y1 receptor, NPY-1, NPYIR,
NPYR, Y1, Y1 RECEPTOR, Y1-R
neuropeptide Y receptor Y1 205440_s_at
PCM1 2600002H09Rik, 9430077F19Rik, C030044G17Rik, LOC100044052,
MGC170660, PTC4
pericentriolar material 1 214118_x_at
PDZK1 1700023D20Rik, 2610507N21Rik, 4921513F16Rik, AI267131, AI314638,
AL022680, CAP70, CLAMP, D3Ertd537e, mPDZK1, NHERF3, PDZD1,
Sodium sulfate cotransporter
PDZ domain containing 1 205380_at
PTPN14 C130080N23RIK, MGC126803, OTTMUSG00000022087, PEZ, PTP36, PTPD2 protein tyrosine phosphatase, non-receptor type 14 205503_at
PVR 3830421F03Rik, CD155, D7ERTD458E, FLJ25946, HVED, mE4, NECL5,
NECTIN 2 ALPHA, NECTIN-2, Pe4, PVS, TAA1, TAGE4
poliovirus receptor 212662_at
RPS15 EG633683, MGC111130, RIG ribosomal protein S15 200819_s_at
RRM2 AA407299, MGC113712, MGC116120, R2, Ribonucleoside-diphosphate
reductase M2 subunit, Ribonucleotide reductase non-heme subunit,
RIBONUCLEOTIDE REDUCTASE SMALL SUBUNIT, Rnr-r2, RNRII, RR2, RR2M
ribonucleotide reductase M2 polypeptide 209773_s_at
SEL1L AW493766, IBD2, KIAA4137, mKIAA4137, PRO1063, SEL1, SEL1-LIKE, SEL1H sel-1 suppressor of lin-12-like (C. elegans) 202063_s_at
SLC39A6 Ermelin, LIV-1 solute carrier family 39 (zinc transporter), member 6 202088_at
TMBIM4 0610007H07Rik, AU022431, CGI-119, GAAP, MGC73002, S1R, ZPRO transmembrane BAX inhibitor motif containing 4 219206_x_at
UBE2B 17-kDa Ubiquitin-Conjugating Enzyme E2, 2610301N02RIK, E2-14K,
E2-17kDa, E2b, HHR6B, HR6B, LOC81816, RAD6B, UBC2
ubiquitin-conjugating enzyme E2B (RAD6 homolog) 211763_s_at
VEGFA Gd-vegf, MGC70609, VEGF, Vegf-3, VEGF1, VEGF120, VEGF164, Vegf165,
Vegf188, Vegfa 188, VPF, VPF/VEGF




PLoS ONE | www.plosone.org 13 December 2009 | Volume 4 | Issue 12 | e8250Table 10. The 40 cancer related genes of the 100 features selected by SVMRFE on original training group of MAQC-II breast cancer
data for erpos prediction.
Symbol Synonym(s) Entrez Gene Name Affymetrix
ANGPTL4 ANGIOPOIETIN-LIKE 4, ANGPTL2, ARP4, Bk89, Fasting Induced Adipose Factor,
FIAF, Harp, HFARP, LOC362850, Ng27, NL2, PGAR, PGARG, pp1158, PPARG
angiopoietin-like 4 221009_s_at
APP A beta 25–35, A-BETA 40, A-BETA 42, AAA, ABETA, ABPP, AD1, Adap, AL024401,
AMYLOID BETA, AMYLOID BETA 40, AMYLOID BETA 40 HUMAN, AMYLOID BETA
42, Amyloid beta A4, AMYLOID BETA PEPTIDE 40, Amyloid precursor,
Amyloidogenic glycoprotein, App alpha, APPI, appican, BETAAPP, CTFgamma,
CVAP, E030013M08RIK, Nexin II, P3, PN2, PreA4, PROTEASE NEXIN2
amyloid beta (A4) precursor protein 214953_s_at
CHRNB4 Acrb-4, NACHR BETA4 cholinergic receptor, nicotinic, beta 4 207516_at
CREBL2 AI046348, B230205M03, MGC109304, MGC117311, MGC130380, MGC130381,
MGC138362
cAMP responsive element binding protein-like 2 201990_s_at
CTSL2 1190035F06Rik, Cathepsin l, CATHEPSIN V, CATHL, CATL2, Ctsl, Ctsl1, CTSU,
CTSV, fs, MEP, MGC125957, nkt
cathepsin L2 210074_at
CX3CL1 AB030188, ABCD-3, AI848747, C3Xkine, CX3C, CX3CL, CXC3, CXC3
CHEMOKINE PRECURSOR, CXC3C, D8Bwg0439e, FK, FKN, FRACTALKINE,
NEUROTACTIN, NTN, NTT, SCYD1
chemokine (C-X3-C motif) ligand 1 823_at
DACH1 AI182278, Dac, DACH, E130112M23Rik, FLJ10138 dachshund homolog 1 (Drosophila) 205471_s_at
E2F1 E2f, E2f1 predicted, KIAA4009, mKIAA4009, RBAP1, RBBP3, RBP3 E2F transcription factor 1 204947_at
EPOR EP-R, ERYTHROPOIETIN RECEPTOR, MGC108723, MGC138358 erythropoietin receptor 215054_at
ERBB4 C-erb-b4, Erbb4 Cyt2, ERBB4 JM-A, HER4, MGC138404, p180erbB4 v-erb-a erythroblastic leukemia viral oncogene
homolog 4 (avian)
214053_at
ESR1 AA420328, Alpha estrogen receptor, AU041214, DKFZp686N23123, ER, ER
ALPHA, Er alpha (46 kDa isoform), ER66, ERA, ER[a], ESR, ESRA, ESTR, ESTRA,
ESTROGEN RECEPTOR ALPHA, ESTROGEN RECEPTOR1, NR3A1, RNESTROR, TERP-1
estrogen receptor 1 217190_x_at
FAM152A 5830417C01Rik, C1orf121, CGI-146, DKFZp586C1019, FLJ21998, PNAS-4 family with sequence similarity 152, member A 212371_at
FBLN1 FBLN, FIBULIN 1 fibulin 1 207834_at
GATA3 HDR, MGC2346, MGC5199, MGC5445 GATA binding protein 3 209602_s_at
GHR AA986417, GHBP, GHR/BP, GROWTH HORMONE RECEPTOR, MGC124963,
MGC156665
growth hormone receptor 205498_at
GPC3 DGSX, Glypican 3, GTR2-2, MGC93606, OCI-5, SDYS, SGB, SGBS, SGBS1 glypican 3 209220_at
GREB1 5730583K22Rik, 9130004E13, AF180470, AU023194, KIAA0575, mKIAA0575 GREB1 protein 205862_at
IGF2BP3 2610101N11Rik, AA522010, Ab2-255, AL022933, AU045931, DKFZp686F1078,
IMP-3, KOC1, Koc13, mimp3, Neilsen, RGD1306512, VICKZ3
insulin-like growth factor 2 mRNA binding protein 3 203820_s_at
IL6ST 5133400A03Rik, AA389424, Ac1055, BB405851, CD130, CDw130, D13Ertd699e,
GP130, GP130-RAPS, Il6 transd, IL6R-beta
interleukin 6 signal transducer (gp130, oncostatin M
receptor)
212195_at
IRS1 ENSMUSG00000022591, G972R, HIRS-1, IRS1IRM insulin receptor substrate 1 204686_at
ITGB4 AA407042, C230078O20, CD104, INTEGRIN-BETA 4 integrin, beta 4 204990_s_at
ITPR1 D6Pas2, I145TR, InsP3R, INSP3R1, IP3 RECEPTOR, Ip3 Receptor Type 1,
IP3R, IP3R1, opt, P400, Pcd6, Pcp-1, SCA15, SCA16
inositol 1,4,5-triphosphate receptor, type 1 211323_s_at
LMO4 A730077C12Rik, Crp3, Etohi4, MGC105593 LIM domain only 4 209205_s_at
MFAP3L 4933428A15RIK, 5430405D20Rik, AI461995, AW125052, KIAA0626,
mKIAA0626, NYD-sp9
microfibrillar-associated protein 3-like 210493_s_at
MGMT AGAT, AGT, AI267024, ATase, MGC107020, O6-ALKYLGUANINE DNA
ALKYLTRANSFERASE
O-6-methylguanine-DNA methyltransferase 204880_at
PCNA MGC8367, Pcna/cyclin, PCNAR proliferating cell nuclear antigen 217400_at
PGR 9930019P03Rik, BB114106, ENSMUSG00000074510, LOC360433, NR3C3, Pgrb,
PR, PR BETA, PR-A, PR-B, PROGESTERONE RECEPTOR, Progesterone receptor A
progesterone receptor 208305_at
PLD1 AA536939, C85393, Pc-Plc, Phospholipase D1, PLD1A, PLD1B, Plda, Pldb phospholipase D1, phosphatidylcholine-specific 215723_s_at
PML 1200009E24Rik, AI661194, MYL, PP8675, Retinoic acid receptor, RGD1562602,
RNF71, TRIM19
promyelocytic leukemia 211013_x_at
PVR 3830421F03Rik, CD155, D7ERTD458E, FLJ25946, HVED, mE4, NECL5,
NECTIN 2 ALPHA, NECTIN-2, Pe4, PVS, TAA1, TAGE4
poliovirus receptor 212662_at
RARRES1 5430417P09RIK, AI662122, TIG1, Tig1/retinoic acid receptor responder 1 retinoic acid receptor responder (tazarotene induced) 1 206391_at
SCGB1D2 BU101, LIPB, LIPOPHILIN B, LPHB secretoglobin, family 1D, member 2 206799_at
SEL1L AW493766, IBD2, KIAA4137, mKIAA4137, PRO1063, SEL1, SEL1-LIKE, SEL1H sel-1 suppressor of lin-12-like (C. elegans) 202063_s_at
SERPINA5 4933415L04, MGC93420, PAI-3, PCI, Pi5 alpha1, PLANH3, PROCI serpin peptidase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 5
209443_at
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on the multiple myeloma dataset. Experimental results again
manifest that gene selection is strictly coupled to learning classifier
in performance measurement. On average, RFA methods and
LOOCSFS are superior to SVMRFE.
Discussion
Due to a huge number of variables and small sample size,
there are complicated interactions and relations among genes as
well as high redundancy information with microarray data. The
selection of predictive models that depend on selected features
a n de m p l o y e dc l a s s i f i e r si se x t r e m e l yi m p o r t a n tf o rt h e
classification of microarray data and for the further biological
function analysis/validation. Machine learning and data mining
techniques provide us with a powerful approach to the study of
the relationship among genes. Based on supervised learning and
similarity measurements, we propose a Recursive Feature
Addition (RFA), recursively employ supervised learning to
obtain the highest training accuracy and add a subsequent
gene based on the similarity between the chosen features and
the candidates to minimize the redundancy within the feature
set. We believe this RFA method captures more informative and
differently expressed genes than other methods. Experimental
comparisons are performed by using two MAQC-II microarray
datasets, breast cancer and multiple myeloma. Our studies show
that the method of gene selection is strictly paired with learning
classifier, which determines the final predictive model by using
training data. In other words, the best classification models
under different learning classifiers are associated with different
methods of gene selection. Using several popular learning
classifiers including NMSC, NBC, SVM, and UDC, on average,
the best method of gene selection is RFA, followed by GLGS,
LOOCSFS, and SVMRFE. Regarding compared learning
classifiers, NMSC outperforms the others with respect to testing
performance, stabilization, and consistency.
Biological function analysis based on MAQC-II breast cancer
dataset finds that our applied feature selection methods including
RFA, GLGS, LOOCSFS, and SVMRFE can generate features
containing a significant portion of known cancer related genes for
both pCR and erpos endpoints (Tables 1–10). Although the cancer
related gene number is not absolutely correlated with the
prediction performance of various methods of feature selection,
the remarkable cancer related genes in the features indicate that
the feature selection methods including RFA, GLGS, LOOCSFS,
and SVMRFE could produce biologically meaningful features,
which will convince the users to apply them for phenotype
prediction.
In all results of the five gene selection methods with the four
learning classifiers, on average, the combination of gene selections
of NMSC-MSC and NBC-MSC with the learning classifier of
NMSC has performed the best, regarding the comprehensive
evaluation criteria of testing accuracy, MCC values, and AUC
errors. It should be noted that the gene selection methods of
NMSC-MSC and NBC-MSC are not always the best over the four
learning classifiers, in other words, the best models among
different learning classifiers are associated with different gene
selection methods. The selection of the best model with the use of
a specific learning classifier is normally based on the training and
the evaluation criteria. Under an evaluation criterion with the use
of some learning classifier, the best training model among the five
gene selection methods is selected as the best model under the
learning classifier. To select the best model among the four
learning classifiers, the best models among the four learning
classifiers are compared and the model obtaining the highest
evaluation score is generally selected the best among the five gene
selection methods and the four learning classifiers. For instance,
Figure 7 demonstrates the average training performance of
MAQC-II breast cancer dataset over twenty times, with the
measurements of training accuracy, MCC values, and AUC
errors, for the classification of pCR endpoint status. Regarding the
comprehensive evaluation of the three criteria, the best classifica-
tion models are obtained by using gene selection method NMSC-
MSC for learning classifier NMSC, NBC-MSC for NBC classifier,
and NBC-MSC and SVMRFE for UDC classifier. With the use of
SVM classifier, although the gene selection method of SVMRFE
first hits the best training as the feature dimension increases,
almost all gene selection methods achieve the best before the
feature number increases to 100, in such case, it is hard for us to
determine the best model with the use of learning classifier SVM.
In the limit of feature number, we can say that SVMRFE is the
best for SVM classifier. The comparison between the training
(Figure 7) and the testing (Figure 2) shows that such selection of the
best model among the various methods of gene selection and
various learning classifiers is reasonable.
Regarding different evaluation criteria, the gene selection
associated with the best model under a learning classifier may be
different, as shown in Figure 7; with the use of learning classifier
Symbol Synonym(s) Entrez Gene Name Affymetrix
SERPINA6 AI265318, AV104445, CBG, MGC112780 serpin peptidase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 6
206325_at
SLC7A5 4f2 light chain, 4F2LC, CD98, CD98 LIGHT CHAIN, CD98LC, D0H16S474E,
D16S469E, E16, E16/TA1, hLAT1, LAT1, MPE16, TA1
solute carrier family 7 (cationic amino acid





4933439A12Rik, HYA1, HYAL1, HYAL3, HYAL5, MGC108951, MGC26532, PH-20,
SPAG15, SPAM1, TESTICULAR HYALURONIDASE
sperm adhesion molecule 1 (PH-20 hyaluronidase,
zona pellucida binding)
210536_s_at
TBC1D9 4933431N12RIK, AI847101, AW490653, C76116, KIAA0882, MDR1, RGD1308221 TBC1 domain family, member 9 (with GRAM domain) 212956_at
TFRC 2610028K12Rik, AI195355, AI426448, AU015758, CD71, E430033M20Rik, Mtvr-1,
p90, TFNR, TFR, TFR1, TRANSFERRIN RECEPTOR, TRFR
transferrin receptor (p90, CD71) 208691_at
TRPV6 ABP/ZF, Cac, CAT, CAT-L, CAT1, Crac, ECAC2, HSA277909, LP6728, Otrpc3, ZFAB transient receptor potential cation channel,
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method of NMSC-MSC, evaluated by training accuracy and
MCC values, the best model is associated with SVMRFE,
evaluated by AUC errors. Overall, NMSC-MSC is the best for
learning classifier NMSC. Figure 7 shows that dozens of the best
training models are obtained by using different methods of gene
selection with the use of SVM classifier. One possible solution
for the selection of the best model under SVM classifier is to
divide all data points into training set, validation set, and testing
set. The training set is used to construct training models, the
validation set is used to select the best model by applying the
validation data to the best training models and selecting the best
Figure 1. Comparison of different gene selection methods for prediction of erpos status of MAQC-II breast cancer dataset with
different learning classifiers. X-axis shows the number of used features and Y-axis shows average values of the testing accuracy (left column),
MCC values (middle column), and AUC errors (right column) of twenty-time experiments, respectively.
doi:10.1371/journal.pone.0008250.g001
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testing set is used for prediction or testing. The selection of the
best model using SVM classifier is very interesting and
challenging, especially in the case of small data points and
huge number of features. Although the topic is beyond the scope
of this paper, it is worthy to be explored in the future study.
Materials and Methods
MAQC-II Breast Cancer Dataset
The breast cancer dataset used in the MAQC-II project is
used to predict the pre-operative treatment response (pCR) and
estrogen receptor status (erpos) [28]. The normalization was
Figure 2. Comparison of different gene selection methods for prediction of pCR status of MAQC-II breast cancer dataset with
different learning classifiers. X-axis shows the number of used features and Y-axis shows average values of the testing accuracy (left column),
MCC values (middle column), and AUC errors (right column) of twenty-time experiments, respectively.
doi:10.1371/journal.pone.0008250.g002
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MAS 5.0 for Affymetrix platform). It was originally grouped into
two groups: a training set contain i n g1 3 0s a m p l e s( 3 3p o s i t i v e s
and 97 negatives for pCR, 80 positives and 50 negatives for
erpos), and a validation set containing 100 samples (15 positives
and 85 negatives for pCR, 61 positives and 39 negatives for
erpos).
MAQC-II Multiple Myeloma Dataset
We take the MAQC-II multiple myeloma dataset to predict the
overall survival milestone outcome (OSMO, 730-day cutoff) and to
predict event-free survival milestone outcome (EFSMO, 730-day
cutoff). For OSMO label information, there are 51 positives and
289 negatives in original training set, 27 positives and 187
negatives in original validation set; as for EFSMO label
Table 11. Mean values and standard errors of HS_HR and MS_HR on ERPOS prediction in the study of MAQC-II breast cancer
dataset. In applying each classifier with each measurement, the best prediction value is in bold; the best prediction value of the
results using the four learning classifiers is in bold and italic.
MEASURE-MENTS GENE SELECTION METHOD MEAN(HS_HR)6STD(HS_HR), % MEAN(MS_HR)6STD(MS_HR), %
NMSC SVM NBC UDC NMSC SVM NBC UDC
Testing Accuracy NBC-MSC 89.562.2 79.362.2 82.961.1 91.661.7 88.561.4 76.560.5 81.760.3 91.061.6
NMSC-MSC 90.662.8 73.360 85.462.8 93.060.8 86.961.5 68.361.6 83.761.9 91.661.1
GLGS 89.762.1 83.862.1 86.861.8 90.561.4 89.261.7 80.360.9 85.761.7 90.261.3
LOOCSFS 86.460.8 66.761.9 86.961.4 86.361.6 86.160.8 65.160.9 86.261.0 85.861.4
SVMRFE 77.367.2 84.460 77.666.6 77.568.9 75.666.7 78.460.1 76.766.1 75.867.6
MCC values NBC-MSC 76.764.5 56.164.7 63.162.3 81.963.7 75.363.3 50.561.0 60.460.7 81.063.4
NMSC-MSC 79.165.8 44.860 66.665.6 84.562.4 72.264.1 34.463.5 64.464.2 82.762.5
GLGS 77.463.6 67.164.9 71.363.9 79.563.2 76.963.4 59.262.3 69.763.8 79.162.7
LOOCSFS 70.861.7 27.065.6 70.963.3 69.763.3 70.561.8 24.463.0 70.262.9 69.663.3
SVMRFE 51.9614.5 66.660 53.9611.9 53.8616.6 51.0613.9 53.860.3 53.5611.5 52.3615.0
AUC errors NBC-MSC 8.560.4 19.562.2 22.260.5 25.764.4 8.560.3 22.260.7 22.260.5 25.764.4
NMSC-MSC 8.460.7 23.560.4 23.161.3 17.163.6 8.460.7 28.262.3 23.161.3 17.163.6
GLGS 8.060.4 10.361.8 16.761.0 15.161.5 8.060.4 13.461.1 16.761.0 15.161.5
LOOCSFS 11.162.2 32.362.7 15.560.5 17.562.6 11.162.2 32.961.8 15.560.5 17.562.6
SVMRFE 17.366.1 14.160 15.360.6 17.362.9 17.366.1 19.160.1 15.360.6 17.362.9
doi:10.1371/journal.pone.0008250.t011
Table 12. Mean values and standard errors of HS_HR and MS_HR on pCR prediction in the study of MAQC-II breast cancer dataset.
In applying each classifier with each measurement, the best prediction value is in bold; the best prediction value is in bold and
italic of the results by using four classifiers.
MEASURE-MENTS GENE SELECTION METHOD MEAN(HS_HR)6STD(HS_HR), % MEAN(MS_HR)6STD(MS_HR), %
NMSC SVM NBC UDC NMSC SVM NBC UDC
Testing Accuracy NBC-MSC 88.762.3 88.960 90.961.0 88.660.8 87.561.9 83.160.3 86.660.6 87.761.6
NMSC-MSC 90.462.1 86.760.0 85.362.2 79.667.7 88.662.7 79.860.7 82.962.0 78.967.4
GLGS 81.264.1 81.960.8 79.461.0 77.065.2 80.864.3 76.260.6 79.161.0 76.565.2
LOOCSFS 77.061.1 82.160.5 72.161.7 74.163.1 76.661.2 78.162.5 71.461.8 73.262.7
SVMRFE 81.962.9 88.960 79.162.6 80.761.9 80.962.7 85.360.2 77.962.3 80.361.8
MCC values NBC-MSC 62.566.7 63.960 69.763.4 60.762.8 61.365.9 48.860.6 54.762.1 59.265.0
NMSC-MSC 68.466.5 55.260 47.767.4 43.9616.0 63.367.9 37.861.9 40.965.0 42.2614.9
GLGS 36.269.5 43.063.5 29.363.5 30.3610.2 35.469.8 29.261.2 28.462.8 30.0610.3
LOOCSFS 23.464.9 38.563.5 18.764.7 21.6611.0 23.065.1 26.365.1 18.265.0 21.1610.7
SVMRFE 40.967.9 62.560.0 32.666.9 41.164.7 39.467.4 49.160.7 30.565.5 40.764.9
AUC errors NBC-MSC 17.262.2 23.261.1 40.065.6 34.866.3 17.262.2 27.560.3 40.065.6 34.866.3
NMSC-MSC 14.463.0 19.160 47.963.7 46.065.1 14.463.0 28.261.1 47.963.7 46.065.1
GLGS 22.661.3 29.360 37.461.8 36.761.8 22.661.3 33.560.3 37.461.8 36.761.8
LOOCSFS 27.561.3 22.861.4 45.863.8 41.663.1 27.561.3 27.162.2 45.863.8 41.663.1
SVMRFE 20.064.4 18.865.7 38.763.4 38.462.0 20.064.3 25.660.2 38.763.4 38.462.0
doi:10.1371/journal.pone.0008250.t012
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training set, 34 positives and 180 negatives in original validation
set [28]. The normalization was provided by MAQC-II project
research group.
Feature Selection
Supervised recursive learning. Our method of recursive
feature addition (RFA) employs supervised learning to achieve the
best training accuracy and uses statistical similarity measures to
choose the next variable with the least dependence on, or
correlation to, the already identified variables as follows:
1. Insignificant genes are removed according to their statistical
insignificance. Specifically, a gene with a high p-value is usually
not differently expressed and therefore has little contribution to
classification of microarray data. To reduce the computational
load, those insignificant genes are removed.
2. Each individual gene is selected by supervised learning. A gene
with highest classification accuracy is chosen as the most
important feature or the first element of the feature set. If
multiple genes achieve the same highest classification accuracy,
the one with the lowest p-value measured by test-statistics (e.g.,
score test), is identified as the first element. At this point the
Figure 3. Average erpos prediction performance by using MAQC-II breast cancer dataset with the measurements testing accuracy
(left column), MCC values (middle column), and AUC errors (right column), respectively. Classification models are setup based on the
best training. In each column, the best combination of gene selection and classifier is highlighted by a red dash circle. If there are multiple best
combinations, or the difference of these combinations is not conspicuous, multiple circles are placed.
doi:10.1371/journal.pone.0008250.g003
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corresponding to the feature dimension one.
3. The (N+1)
st dimensional feature set, GN+1={g1, g2,… ,gN, gN+1}
is obtained by adding gN+1 to the N
th dimensional feature set,
GN={g1, g2,… ,gN}. The choice of gN+1 is processed as follows:
4. Add each gene gi (gi 6[ GN) into GN and have the classification
accuracy of the feature set GN | {gi}. The gi (gi 6[ GN)
associated with the group, GN | {gi} that obtains the highest
classification accuracy, is the candidate for gN+1 (not yet gN+1).
Considering the large number of variables, it is very likely that
multiple features correspond to the same highest classification
accuracy, these multiple candidates are placed into the set C,
but only one candidate in C will be identified as gN+1. How to
make the selection is described next.
Candidate feature addition. To find a most informative (or
least redundant) candidate for gN+1, we measure the statistical
similarity between the chosen features and each candidate. We
design a similarity measurement with the use of a widely-used
Pearson’s correlation coefficient [30].
Suppose gn (gn [ GN, n=1,2,…,N) is a chosen gene, gc (gc [ C)i s
a candidate gene, and cor stands for the function of Pearson’s
correlation coefficient. The sum of the square of the correlation
Figure 4. Average pCR prediction performance by using MAQC-II breast cancer dataset with the measurements testing accuracy
(left column), MCC values (middle column), and AUC errors (right column), respectively. Classification models are setup based on the
best training. In each column, the best combination of gene selection and classifier is highlighted by a dash circle.
doi:10.1371/journal.pone.0008250.g004
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SC gc ðÞ ~
X N
n~1
cor2 gc, gn ðÞ , n~1, 2 ... N ð1Þ
Then selection of gN+1 is based on Minimal value of the Square
of the Correlation (MSC), that is,
gNz1/ gcjSC gc ðÞ ~min(SC),gc[C fg ð2Þ
In the methods mentioned above, a feature is recursively added
to the chosen feature set based on supervised learning and the
similarity measurement. In our experiments we choose naı ¨ve bayes
classier (NBC) and nearest means scale classifier (NMSC) [29] for
supervised learning, NBC and NMSC-based RFA feature
selection methods are denoted as NBC-MSC and NMSC-MSC,
respectively.
Model Implementation and Comparison
Cross-validation is a technique for estimating how accurately
a predictive model will perform in practice. Generally, the data
Figure 5. Average EFSMO prediction performance by using MAQC-II multiple myeloma dataset with the measurements testing
accuracy (left column), MCC values (middle column), and AUC errors (right column), respectively. Classification models are setup based
on the best training. In each column, the best combination of gene selection and classifier is highlighted by a dash circle.
doi:10.1371/journal.pone.0008250.g005
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the training set) is used for constructing the predictive model
and the other subset (called the validation set or testing set) is
used for validation. To reduce variability, multiple rounds are
performed using different partitions, and the validation results
are averaged over all rounds. There are three common types of
cross-validation:
1) Repeated random sub-sampling validation. This technique
randomly splits the dataset intro training and testing data.
The results are then averaged over the splits. The advantage
over K-fold cross validation (described below) is that the
portion of the training/testing split is not dependent on the
number of iterations (folds);
2) K-fold cross-validation. The original sample is partitioned
into K subsamples. A single subsample is retained as the
validation data for testing the model and the remaining K-1
subsamples are used as training data. The cross-validation
process is repeated K times with each of the K subsamples
used exactly once as the validation data;
Figure 6. Average OSMO prediction performance by using MAQC-II multiple myeloma dataset with the measurements testing
accuracy (left column), MCC values (middle column), and AUC errors (right column), respectively. Classification models are setup based
on the best training. In each column, the best combination of gene selection and classifier is highlighted by a dash circle. If there are multiple best
combinations, or the difference of these combinations is not conspicuous, multiple circles are placed.
doi:10.1371/journal.pone.0008250.g006
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from the original sample as the validation data and the
remaining observations as the training data. It is the same as
a K-fold cross validation with K being equal to the number of
observations in the original sample. Leave-one-out cross-
validation is often computationally expensive.
Considering the high computational requirement of leave-one-
out cross-validation and the insufficiency of one time K-fold cross-
validation, we took the strategy of repeated random sub-sampling
validation. In the model implementation, we mixed all the training
data points and validation points. In each experiment, we
randomly chose 80% of samples for training and the remaining
Figure 7. Comparison of different gene selection methods for the training of pCR endpoint of MAQC-II breast cancer dataset using
the four classifiers. X-axis shows the number of used features and Y-axis shows average values of the training accuracy (left column), MCC values
(middle column), and AUC errors (right column) of twenty-time experiments, respectively.
doi:10.1371/journal.pone.0008250.g007
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PLoS ONE | www.plosone.org 23 December 2009 | Volume 4 | Issue 12 | e825020% of samples for testing. Twenty experiments were performed
(this strategy is approximately equal to performing 5-fold cross
validation four times). The average testing performances, evalu-
ated in terms of testing accuracy, MCC values, and AUC errors,
were compared. The learning classifiers UDC, NBC, NMSC, and
SVM were employed for training and testing.
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